Mark Kupersmith, MD Email Mark Kupersmith
- PROFESSOR | Neurology
- PROFESSOR | Ophthalmology
- PROFESSOR | Neurosurgery
- Hospital Affiliations
- Mount Sinai St. Luke's and Mount Sinai West
- The Mount Sinai Hospital
- Mount Sinai Beth Israel
- New York Eye and Ear Infirmary of Mount Sinai
Click here to read Dr. Kupersmith's CV.
AAO Honor Award
North American Neuro-Ophthalmology Society Distinguished Service Award 2009
Hoyt Lecture AAO 2014
Neurology, American Board of Psychiatry and Neurology
- Arteriovenous Malformation of the Brain
- Bell's Palsy
- Cavernous Malformations
- Myasthenia Gravis
- Neuromyelitis Optica
- Optic Neuritis
- Pituitary Adenoma
- Pituitary Tumor
- Temporal Arteritis
MRI, Neuroscience, Vision
MD, Northwestern University Medical School
NYU Medical Center
NYU Medical Center
English, SpanishDownload the CV
I have serve as Chair of the planning committee for NORDIC and directed NORDIC (February 2009-present), fulfilling all of the obligations outlined in NORDIC policies and in the Idiopathic Intracranial Hypertension Treatment Trial, the LIIHTT and for proposed studies, HIS and SiihTT. I intend to continue in the same capacity now as Director of the Enrollment and Resource Centers, administratively integrating studies, sites, investigators, reading centers, Data Coordinating and Biostatistical Center, managing sites and committees and overseeing finance, and scientifically contributing to the multi-site studies conducted across the US and Canada by NORDIC (Neuro-Ophthalmology Research Disease Investigator Consortium).
I direct an ECRIP center award at NYEEI, title 'Noninvasive optical imaging detection of changes in the peripapillary retina and optic nerve head due to damage of the optic nerve' which is currently studying glaucoma, optic neuritis, NAION, giant cell arteritis, and NMO. Each project is headed by a 'fellow' who are all subspecialty trained ophthalmologists or neurologists.
Sibony P, Kupersmith MJ, Honkanen R, Rohlf FJ, Torab-Parhiz A. Effects of lowering cerebrospinal fluid pressure on the shape of the peripapillary retina in intracranial hypertension. Investigative ophthalmology & visual science 2014 Dec; 55(12).
Auinger P, Durbin M, Feldon S, Garvin M, Kardon R, Keltner J, Kupersmith MJ, Sibony P, Plumb K, Wang JK, Werner JS. Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part II: correlations and relationship to clinical features. Investigative ophthalmology & visual science 2014 Dec; 55(12).
Auinger P, Durbin M, Feldon S, Garvin M, Kardon R, Keltner J, Kupersmith M, Sibony P, Plumb K, Wang JK, Werner JS. Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part I: quality control, comparisons, and variability. Investigative ophthalmology & visual science 2014 Dec; 55(12).
Wall M, McDermott MP, Kieburtz KD, Kupersmith MJ. Treating idiopathic intracranial hypertension--reply. JAMA neurology 2014 Oct; 71(10).
Wall M, McDermott MP, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, Kupersmith MJ. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA; 311(16).
Wall M, Kupersmith MJ, Kieburtz KD, Corbett JJ, Feldon SE, Friedman DI, Katz DM, Keltner JL, Schron EB, McDermott MP. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA neurology 2014 Jun; 71(6).
Friedman DI, McDermott MP, Kieburtz K, Kupersmith M, Stoutenburg A, Keltner JL, Feldon SE, Schron E, Corbett JJ, Wall M. The idiopathic intracranial hypertension treatment trial: design considerations and methods. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2014 Jun; 34(2).
Sibony P, Strachovsky M, Honkanen R, Kupersmith MJ. Optical coherence tomography shape analysis of the peripapillary retinal pigment epithelium layer in presumed optic nerve sheath meningiomas. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2014 Jun; 34(2).
Kupersmith MJ, Anderson S, Durbin M, Kardon R. Scanning laser polarimetry, but not optical coherence tomography predicts permanent visual field loss in acute nonarteritic anterior ischemic optic neuropathy. Investigative ophthalmology & visual science 2013 Aug; 54(8).
Kupersmith MJ, Anderson S, Kardon R. Predictive value of 1 month retinal nerve fiber layer thinning for deficits at 6 months after acute optic neuritis. Multiple sclerosis (Houndmills, Basingstoke, England) 2013 Nov; 19(13).
Wang JK, Kardon RH, Kupersmith MJ, Garvin MK. Automated quantification of volumetric optic disc swelling in papilledema using spectral-domain optical coherence tomography. Investigative ophthalmology & visual science 2012 Jun; 53(7).
Bruce BB, Kupersmith MJ. Safety of prednisone for ocular myasthenia gravis. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2012 Sep; 32(3).
Kupersmith MJ, Kardon R, Durbin M, Horne M, Shulman J. Scanning laser polarimetry reveals status of RNFL integrity in eyes with optic nerve head swelling by OCT. Investigative ophthalmology & visual science 2012 Apr; 53(4).
Sibony P, Kupersmith MJ, Rohlf FJ. Shape analysis of the peripapillary RPE layer in papilledema and ischemic optic neuropathy. Investigative ophthalmology & visual science 2011; 52(11).
Kupersmith MJ, Mandel G, Anderson S, Meltzer DE, Kardon R. Baseline, one and three month changes in the peripapillary retinal nerve fiber layer in acute optic neuritis: relation to baseline vision and MRI. Journal of the neurological sciences 2011 Sep; 308(1-2).
Kupersmith MJ, Sibony P, Mandel G, Durbin M, Kardon RH. Optical coherence tomography of the swollen optic nerve head: deformation of the peripapillary retinal pigment epithelium layer in papilledema. Investigative ophthalmology & visual science 2011 Aug; 52(9).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Kupersmith did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.